Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization

Cancer Biology and Therapy

Volumn 8, Issue 21, 2009, Pages 2025-2032

  Chen, Hsin Wei ^a,b   Leng, Chih Hsiang ^a   Liu, Hsin Yu ^a   Cheng, Wen Fang ^c   Chang, Yu Wen ^a   Wu, Pin Yi ^d   Lien, Shu Pei ^a   Huang, Tzu Yi ^a   Chiang, Sheng Kuo ^a   Lin, Min Han ^a   Tao, Mi Hua ^d   Chong, Pele ^a   Liu, Shih Jen ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d ACADEMIA SINICA   (Taiwan)

Author keywords

Cervical cancer; Cytotoxic T lymphocytes; HLA A11; HPV18; Peptide based vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA A11 ANTIGEN; HUMAN PAPILLOMAVIRUS 18 E6 ONCOPROTEIN; PLASMID DNA; PLASMID VECTOR; RECOMBINANT PROTEIN; TETRAMER; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA IMMUNIZATION; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN PAPILLOMAVIRUS TYPE 18; MOUSE; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SPLEEN CELL; TRANSGENIC MOUSE; UTERINE CERVIX CANCER;

EID: 73549088284     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.21.9732     Document Type: Article

References (27)

1. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. International Biological Study on Cervical Cancer Study G. Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide Perspective. J Natl Cancer Inst 1995; 87:796-802.
2. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89:101-5.
3. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunology, Immunotherapy 2008; 57:517-30.
4. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA, et al. A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia Who Are HPV 16 Positive. Clin Cancer Res 2000; 6:3406-16.
5. + T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. Clin Cancer Res 2008; 14:178-87.
6. van Driel WJ, Ressing ME, Kenter GG, Brandt RMP, Krul EJT, van Rossum AB, et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. European Journal of Cancer 1999; 35:946-52.
7. Kather AFA, Nonn M, Schinz M, Nieland J, Schneider A, Dürst M, et al. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. International Journal of Cancer 2003; 104:345-53.
8. McCarthy CYS, Man S. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. International Journal of Cancer 2006; 118:2514-21.
9. Rudolf MP, Man S, Melief CJM, Sette A, Kast WM. Human T-Cell Responses to HLA-A-restricted High Binding Affinity Peptides of Human Papillomavirus Type 18 Proteins E6 and E7. Clin Cancer Res 2001; 7:788-95.
10. Lin M, Chu CC, Chang SL, Lee HL, Loo JH, Akaza T, et al. The origin of Minnan and Hakka, the so-called "Taiwanese", inferred by HLA study. Tissue Antigens 2001; 57:192-9.
11. Lee TD, Zhao TM, Mickey R, Sun YP, Lee G, Song CX, et al. The polymorphism of HLA antigens in the Chinese. Tissue Antigens 1988; 32:188-208.
12. Sylvester-Hvid C, Kristensen N, Blicher T, Ferr H, Lauemler SL, Wolf XA, et al. Establishment of a quantitative ELISA capable of determining peptide-MHC class I interaction. Tissue Antigens 2002; 59:251-8.
13. Lee SP, Tierney RJ, Thomas WA, Brooks JM, Rickinson AB. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997; 158:3325-34.
14. Martin P, Simon B, Lone Y-C, Chatel L, Barry R, Inchausp G, et al. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008; 26:2471-81.
15. Golovina TN, Wherry EJ, Bullock TNJ, Eisenlohr LC. Efficient and Qualitatively Distinct MHC Class I-Restricted Presentation of Antigen Targeted to the Endoplasmic Reticulum. J Immunol 2002; 168:2667-75.
16. Chang L, Kjer-Nielsen L, Flynn S, Brooks AG, Mannering SI, Honeyman MC, et al. Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. Tissue Antigens 2003; 62:408-17.
17. Xu W, Chu Y, Zhang R, Xu H, Wang Y, Xiong S. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology 2005; 334:255-63.
18. Evans C, Bauer S, Grubert T, Brucker C, Baur S, Heeg K, et al. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Cancer Immunol Immunother 1996; 42:151-60.
19. Ressing ME, van Driel WJ, Celis E, Sette A, Brandt MP, Hartman M, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996; 56:582-8.
20. Bontkes HJ, de Gruijl TD, van den Muysenberg AJ, Verheijen RH, Stukart MJ, Meijer CJ, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. Int J Cancer 2000; 88:92-8.
21. Evans EM, Man S, Evans AS, Borysiewicz LK. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 1997; 57:2943-50.
22. Valdespino V, Gorodezky C, Ortiz V, Kaufmann AM, Roman-Basaure E, Vazquez A, et al. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecol Oncol 2005; 96:92-102.
23. Liu DW, Yang YC, Lin HF, Lin MF, Cheng YW, Chu CC, et al. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLAA* 0201-restricted T-cell peptides in cervical cancer patients. J Virol 2007; 81:2869-79.
24. Stuber GMS, Höglund P, Franksson L, Elvin J, Wolf H, Kärre K, et al. Assessment of major histocompatibility complex class I interaction with Epstein-Barr virus and human immunodeficiency virus peptides by elevation of membrane H-2 and HLA in peptide loadingdeficient cells. European Journal of Immunology 1992; 22:2697-703.
25. Okochi M, Hayashi H, Ito A, Kato R, Tamura Y, Sato N, et al. Identification of HLA-A24-restricted epitopes with high affinities to Hsp70 using peptide arrays. Journal of Bioscience and Bioengineering 2008; 105:198-203.
26. Lee S, Tierney R, Thomas W, Brooks J, Rickinson A. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy. J Immunol 1997; 158:3325-34.
27. Dillon PJRC. A rapid method for the construction of synthetic genes using the polymerase chain reaction. Biotechniques 1990; 9:298-300.